Aims/hypothesis A contributor to beta cell failure in type 2 diabetes and islet transplants is amyloid formation by aggregation of the beta cell peptide, islet amyloid polypeptide (IAPP). Similar to the proinsulin processing pathway that generates insulin, IAPP is derived from a prohormone precursor, proIAPP, which requires cleavage by prohormone convertase (PC) 1/3 and PC2 in rodent pancreatic beta cells. We hypothesised that loss of PC2 would promote beta cell death and dysfunction in a rodent model of human beta cell proIAPP overexpression. Methods We generated an islet transplant model wherein immune-deficient mouse models of diabetes received islets expressing amyloidogenic human proIAPP and lacking PC2, leading to restoration of normoglycaemia accompanied by increased secretion of human proIAPP. Blood glucose levels were analysed for up to 16 weeks in transplant recipients and grafts were assessed for islet amyloid and beta cell number and death. Results Hyperglycaemia (blood glucose >16.9 mmol/l) returned in 94% of recipients of islets expressing human proIAPP and lacking PC2, whereas recipients of islets that express human proIAPP and normal PC2 levels remained normoglycaemic for at least 16 weeks. Islet graft failure was accompanied by a ∼20% reduction in insulin-positive cells, yet the degree of amyloid deposition and beta cell apoptosis was similar to those of controls expressing human proIAPP with functional PC2 levels. Conclusions/interpretation PC2 deficiency in transplanted mouse islets expressing human proIAPP promotes beta cell loss and graft failure. Our data suggest that impaired NH 2 -terminal processing and increased secretion of human proIAPP promote beta cell failure.
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Introduction
Islet amyloid creates pathological lesions in the pancreas of type 2 diabetic individuals [1] . The major component of amyloid is islet amyloid polypeptide (IAPP), a self-aggregating hormone, co-secreted with insulin from beta cells [2, 3] . Misfolded IAPP monomers assemble into oligomeric intermediates, which further generate amyloid fibres containing heparan sulphate proteoglycans, serum amyloid P and apolipoprotein E [4] [5] [6] . Prefibrillar IAPP species that arise during the transition from monomer to amyloid fibril elicit beta cell dysfunction and apoptosis [7] [8] [9] , and provoke islet inflammation [9] [10] [11] . Cytotoxic IAPP aggregates mediate beta cell death and dysfunction in type 2 diabetes and in transplanted human islets [10, [12] [13] [14] , although the mechanisms leading to cytotoxicity are poorly understood. Adequate prohormone processing is vital to blood glucose homeostasis. Proinsulin processing is impaired in both type 2 diabetes [15] [16] [17] and islet transplants [18] , resulting in elevated proinsulin:C-peptide ratios. Proinsulin processing involves cleavage by prohormone convertase (PC) 1/3 and PC2 in order to generate insulin and C-peptide [17, 19] . In PC2-deficient mice, the absence of PC2 is partially compensated by the action of PC1/3 [20] ; however, mice lacking PC2 still have elevated levels of proinsulin [21] , a molecule with 10% bioactivity relative to insulin [22] . Similarly, in mice, pro-islet amyloid polypeptide (proIAPP) processing requires sequential action by PC1/3 and PC2 to generate IAPP [23, 24] . However, it is unclear whether impaired proIAPP processing plays a role in the pathogenesis of diabetes. Partially processed proIAPP species form aggregate structures in vitro [25, 26] and may be involved in amyloid formation and toxicity. Studying the effect of impaired prohormone processing has been limited by the lack of a suitable model, since global loss of PC2 results in developmental abnormalities [19, 27] and hypoglycaemia [20, 24] .
Overexpression of human proIAPP in PC1/3-and PC2-deficient cell lines promotes increased amyloid deposition and apoptosis [28] . We have previously demonstrated that cultured human proIAPP-overexpressing islets lacking PC2 develop increased amyloid formation and cell apoptosis compared with islets with normal PC2 levels [29] . We hypothesised that impaired beta cell proIAPP processing would further promote beta cell dysfunction in vivo. To test this hypothesis in a model of PC2 deficiency with adequate beta cell secretory drive, we transplanted mouse islets expressing human proIAPP but lacking PC2 into diabetic recipients and assessed graft function and amyloid formation.
Methods
Mice NOD.CB17-Prkdc scid /J (NOD/severe combined immunodeficiency [SCID]), C57BL/6J, FVB/N and FVB/NTg(Ins2-IAPP)RHFSoel/J (human proIAPP transgenic) mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). B6;129-Pcsk2 tm1Dfs /J (Pc2 [also known as Pcsk2]-null) mice were generated as described previously [21] . All animals were housed in the animal facility of the Research Institute, BC Children's Hospital, in a 12 h/12 h light/dark cycle, at 22 ± 2°C, with free access to food and water. Male animals were used as islet donors and recipients.
Pc2-null mice were crossed with human proIAPP transgenic mice to generate hemizygous human proIAPP transgenic animals (hproIAPP Tg Islet isolation and transplantation Islets were isolated from 16-week-old donors as described in the electronic supplementary material (ESM) Methods. NOD/SCID recipients were administered a single dose (180 mg/kg) of streptozotocin (STZ; Sigma, St. Louis, MO, USA) and used for transplant if blood glucose was greater than 20 mmol/l. Mice received 150 islets, which were transplanted into the left renal subcapsular space 4 days after STZ administration. Animals in which blood glucose levels did not normalise in the first week following transplant were removed from the study.
Western blot Islets were isolated from 16-week-old wild-type and Pc2 −/− animals for detection of glucagon and glucagon precursors, using a polyclonal guinea pig anti-mouse glucagon antibody (1:1000; ThermoFisher, Waltham, ME, USA), as described in ESM Methods.
Blood glucose monitoring Blood glucose was measured weekly using a OneTouch Ultra Glucometer (LifeScan, Burnaby, BC, Canada) via tail bleeds in islet donors (prior to islet isolation) and in islet transplant recipients. Graft failure was identified when fasting blood glucose levels were above 16.9 mmol/l, at which point mice were euthanised.
Glucose and insulin tolerance tests To assess glucose tolerance, mice were fasted for 6 h and administered glucose i. terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) staining, using the in situ cell death detection kit (Roche, Mississauga, ON, Canada).
Quantification of immunofluorescent staining
Quantification of immunofluorescent staining was carried out on three representative sections from each group using an Image-Pro Plus Analyzer V6 (Olympus), as described in the ESM Methods. Where possible, experimenters were blind to outcome assessment. Graft beta cell area was determined as the insulin-positive area divided by the total insulin-and glucagon-positive (alpha cell) area and the proportion of TUNEL-positive beta cells was calculated as the number of TUNEL and insulin co-positive cells divided by total insulinpositive cells. Amyloid area was calculated as the thioflavin S positive area divided by total graft area and amyloid severity (%) was calculated as total amyloid area divided by total islet area (×100), while per cent amyloid prevalence was calculated as number of islets containing amyloid divided by total number of islets (×100).
Statistical analyses Data are expressed as mean ± SEM. Differences between two groups were determined using Student's t test, while differences among several groups were analysed by one-way ANOVA followed by Tukey's post hoc test for multiple comparisons. Statistical analyses were performed using GraphPad Prism 5.0 software (GraphPad, La Jolla, CA, USA). Values were considered significant if p < 0.05.
Results

Lack of PC2 promotes mild hypoglycaemia and improved glucose tolerance
To test whether elevated human proIAPP levels promote beta cell failure, we generated mice with beta cell expression of human proIAPP and lacking PC2 (proIAPP
, as well as control mice with human proIAPP and one Pc2 allele (proIAPP (Fig. 1a) . We generated additional control groups of mice that did not express human proIAPP but lacked PC2 (proIAPP − Pc2 − ), as well as mice that did not express human proIAPP and had normal PC2 function (proIAPP (Fig. 1a) . Pc2 +/− mice were used instead of Pc2 +/+ mice for ease of breeding. We first determined whether global PC2 deficiency had an impact on glucose homeostasis, with and without expression of the human proIAPP transgene. FVB;B6 hybrid proIAPP − Pc2 + mice tended to have higher body weight on breeder chow, relative to other genotypes, although this was not statistically significant (Fig. 1b) . None of the four genotypes were hyperglycaemic, although mice lacking PC2 demonstrated mild hypoglycaemia ( Fig. 1c) , likely related to their inability to produce mature glucagon [20] . Lack of mature glucagon production in PC2-deficient animals was demonstrated by western blot (ESM Fig. 1 ). Glucose tolerance was improved in PC2-deficient compared with mice with PC2 expression (Fig. 1c) , as previously reported in PC2-deficient mice fed normal chow [20] . We observed a mild difference in glucose tolerance between proIAPP
+
Pc2
+ and proIAPP − Pc2 + mice at 16 weeks of age, suggesting that expression of the human proIAPP transgene promotes early beta cell dysfunction in our model.
ProIAPP
+
Pc2
− mice have abnormal islet morphology and reduced amyloid formation
To determine whether proIAPP + Pc2 − mice have changes in islet morphology, we determined the proportion of beta to alpha cells in these animals. Mice lacking PC2 had an increased proportion of alpha cells, such that the ratio of beta:alpha cells was ∼1:1 ( Fig. 2a-c) , as reported previously [20] . Interestingly, despite this abnormal islet architecture, proIAPP 
− mice (Fig. 2c-e) . The lack of detectable amyloid in mice expressing human proIAPP and lacking PC2 is likely related to these animals being mildly hypoglycaemic, resulting in a low drive for proIAPP synthesis [30] .
Loss of PC2 and overexpression of human proIAPP lead to rapid failure of islet transplants
Since PC2-deficient mice tend to be hypoglycaemic because of their inability to make mature glucagon, to test whether loss of PC2 promotes amyloid formation and beta cell dysfunction in vivo we transplanted islets from these mice into STZ-induced diabetic, immune-deficient (NOD.SCID) recipients. Recipient mice were predicted to have normal glucagon levels but severely reduced beta cell numbers following STZ administration. We chose islet donors with minimal amyloid deposition and normal glucose tolerance to enable us to investigate differences in phenotype that arise following transplantation. Following islet transplantation and initial normalisation of blood glucose, non-fasting blood glucose levels steadily increased in mice transplanted with islets from proIAPP + Pc2 − mice (Fig. 3a) .
By contrast, we observed no changes in blood glucose levels in recipients of proIAPP
+ islet grafts. Strikingly, in a cohort of islet graft recipients followed for 16 weeks, 15 of 16 recipients of proIAPP − Pc2 − islet transplants became hyperglycaemic (blood glucose >16.9 mmol/l), whereas all recipients of control islet grafts remained normoglycaemic (Fig. 3b) . These results suggest that loss of PC2 promotes beta cell failure in a model of human proIAPP overexpression. We next examined whether islet graft failure was accompanied by amyloid formation and beta cell loss. To determine whether islet graft failure was due to loss of beta cells shortly (Fig. 4a-c) . The proportion of insulin-positive cells in proIAPP + Pc2 − was further reduced compared with proIAPP + Pc2 + islet transplants compared at 6 weeks post transplant, making this finding significant (Fig. 4d, e) . The number of insulin-positive cells per islet 1 week post transplant was similar in proIAPP
+
Pc2
− and proIAPP + Pc2 + islet grafts (ESM Fig. 3a ) but significantly lower in proIAPP
+
Pc2
− at 6 weeks post transplant (ESM Fig. 3b ). These data suggest that most beta cell loss in this model does not occur immediately following transplantation, but rather over several weeks post transplant, possibly as IAPP toxicity accumulates. The proportion of graft area comprising alpha cells was non-significantly higher in proIAPP − Pc2 − compared with proIAPP − Pc2 + islets at 1 week post transplantation (Fig. 4d, e ), but by 6 weeks post transplant, the alpha cell proportion had returned to similar levels as those of proIAPP
−
Pc2
+ islet grafts. Thus, the alpha cell hyperplasia associated with PC2 deficiency was normalised following transplantation of islets into recipients with normal glucagon production. Somewhat surprisingly, thioflavin S staining revealed a similar degree of amyloid deposition in proIAPP + Pc2 − compared with proIAPP + Pc2 + islet grafts (Fig. 4f, g ). While these data do not support amyloid as the major cause of failure of proIAPP
+
Pc2
− islet transplants, it remains possible that non-detectable, prefibrillar amyloid aggregates contributed to graft failure in this model. TUNEL staining revealed no significant differences in islet cell death at 6 weeks post transplant among any of the groups (Fig. 4h, i) .
Elevated proinsulin and human proIAPP levels are associated with early islet graft failure
To better characterise the effect of PC2 loss on prohormone processing in this model, we measured plasma concentrations of mouse proinsulin, human proIAPP 1-48 and mature human IAPP. As expected, at 6 weeks post transplantation, recipients of grafts lacking PC2 had markedly elevated circulating proinsulin levels (Fig. 5a ). By contrast, mouse C-peptide concentrations were similar among all groups (Fig. 5b) . Our finding that C-peptide levels are similar in recipients of Pc2 −/− and Pc2 +/− islet grafts is somewhat surprising, and may arise from compensatory increases in proinsulin production and/or PC1/ 3 synthesis in PC2-deficient beta cells. Circulating levels of the human proIAPP processing intermediate, proIAPP , were elevated in mice that received proIAPP
+
Pc2
− islets compared with recipients of proIAPP + Pc2 + islets (Fig. 5c ), while mature human IAPP levels also tended to be increased in recipients of proIAPP 
− islets (p = 0.054; Fig. 5d ). Since
− islet transplants did not fail during the 16 week study period, our data suggest that elevated proinsulin levels alone are insufficient to promote graft failure; however, the combination of increased proinsulin and proIAPP production by proIAPP
+
Pc2
− islet grafts appears sufficient for rapid transplant failure. We performed insulin tolerance tests in recipients 6 weeks post transplant to ascertain whether transplant failure might be attributed to changes in insulin sensitivity. Compared with mice with proIAPP
+
Pc2
+ grafts, recipients of proIAPP + Pc2 − islets had significantly higher blood glucose levels during the first 30 min of the test (Fig. 5e ) and a greater change in blood glucose levels at 60 and 120 min (Fig. 5f ). These data imply that animals with failing proIAPP + Pc2 − grafts were, if anything, more insulin sensitive, and suggest that hyperglycaemia was a result of impaired graft function and not peripheral insulin resistance. One explanation for the improved insulin sensitivity in recipients of proIAPP + Pc2 − grafts, despite the presence of hyperglycaemia, could be related to bioactivity of the very high circulating proinsulin levels in these mice (Fig. 5a ). 
+ grafts, although, due to high variance and small sample size, these changes were not statistically significant (Fig. 6a) . Immunostaining data supported our gene expression findings: the intensity of PDX1 immunostaining appeared reduced in proIAPP
+
Pc2
− grafts compared with controls (Fig. 6b) . Coinciding with this effect, there was a reduction in PDX1-positive beta cell per cent in proIAPP + Pc2 − grafts (Fig. 6c) , suggesting that graft failure in this model is accompanied by reduced PDX1 production in beta cells. The absence of PDX1 expression in non-insulin-producing cells (Fig. 6b) , as well as the lack of any observable insulin and glucagon co-staining (Fig. 4d) , suggested that there were no changes in pancreatic progenitor cells or occurrence of trans-differentiation at 6 weeks post transplant. We also examined CHOP levels as a late-stage marker of endoplasmic − vs all other islet recipients reticulum (ER) stress-induced apoptosis in failing islet grafts. None of the recipient groups' beta cells stained positive for CHOP (Fig. 6d, ESM Fig. 4) , suggesting that ER stress-induced apoptosis was not a characteristic of islet graft failure in this model, at least at 6 weeks post transplant.
Our own previous data demonstrated that human IAPP aggregates induce inflammation in islet transplants [9] . Islets from proIAPP + Pc2 − donors displayed a trend towards increased Cd11b (also known as Itgam) expression compared with the other groups (Fig. 6e) ; however, no difference was 
− islet grafts (Fig. 6f) . We also observed a trend towards downregulation of Sgne1 (also known as Scg5), which codes for the PC2 chaperone, 7B2, and Cpe, responsible for removal of paired basic residues following PC-mediated cleavage (Fig. 6f ). These data demonstrate the possibility that further impairments in prohormone processing may accompany declining islet graft function in this model.
Discussion
Identification of factors that limit beta cell viability is vital to the understanding of diabetes development. Here, we demonstrate that dysregulation of human proIAPP processing leads to premature beta cell failure in an islet transplant model. Although the degree of amyloid deposition was similar between mice with and without expression of PC2, deficiency of this enzyme in the presence of human proIAPP expression led to significant loss of beta cells. The data suggest a model in which impaired prohormone processing promotes beta cell failure. The toxic species associated with IAPP aggregation remains elusive, although prefibrillar, oligomeric species appear to be most deleterious for beta cell survival [7, 9] . Here, we examined whether overexpression of human proIAPP in a model lacking PC2 production exacerbated beta cell failure. Surprisingly, even with rapid islet graft failure and a ∼20% reduction in insulin-positive cells in islet transplants expressing human proIAPP and lacking PC2, we were unable to detect increases in amyloid deposition or beta cell apoptosis. These observations are in contrast with our previous in vitro findings [29] . Mature amyloid fibrils appear to be less deleterious to beta cells than prefibrillar species and improvements in glucose tolerance do not always correlate with reduced amyloid formation [10] . Thus, while our data do not support the hypothesis that impaired NH 2 -terminal processing of proIAPP leads to amyloid formation in vivo, it remains plausible that increased production of prefibrillar proIAPP aggregates are present in PC2-deficient, human proIAPP-expressing islet grafts and are inducing beta cell dysfunction and death, but that these are not detectable by thioflavin S.
Although aggregation of proIAPP forms has not been studied as extensively as in mature IAPP, it has been reported that proIAPP species aggregate in the presence of negatively-charged artificial membranes [31] . The positively-charged NH 2 -terminus of unprocessed proIAPP interacts with heparin, possibly enabling attachment to heparan sulphate proteoglycans on islet basement membranes and forming a nidus for amyloid development [6, 32, 33] . Whether this process impacts other signalling pathways or is a contributor to beta cell apoptosis has not been examined. Although preliminary, our gene expression analysis suggests that accumulation of human proIAPP species may compromise beta cell differentiation and function, and prohormone processing, and may induce pro-inflammatory pathways. However, a more thorough analysis at the protein level will A previous study revealed that human IAPP expression led to islet transplant failure 2 weeks following transplantation of a suboptimal mass of 100 islets [13] . Because our transplant studies had the additional stress of impaired human proIAPP and proinsulin processing, we chose to transplant a more optimal mass of 150 islets. Islets from PC2-deficient mice showed alpha cell hyperplasia (∼1:1 ratio of beta cells:alpha cells) compared with islets from mice with normal PC2 expression. Despite this abnormal islet morphology, transplanted islets lacking PC2 and without human proIAPP expression remained functional. Immunostaining revealed restoration of normal beta and alpha cell histology in PC2-deficient grafts at 6 weeks post transplant, in keeping with other findings that alpha cell hyperplasia is driven by lack of glucagon production [34] . To avoid potentially confounding effects of the abnormal islet morphology in Pc2-null mice, as well as the limitations of islet transplant models, future studies should examine amyloid formation and beta cell function in a model of beta cell-specific deletion of PC2 and human proIAPP expression.
Whether impaired proIAPP is characteristic of type 2 diabetes has not been determined; however, elevated proinsulin:insulin ratios in circulation have been shown to be markers of beta cell dysfunction in type 1 diabetes [35] , type 2 diabetes [15, 18] and islet transplant failure [18] . In this study, we present an in vivo model in which impaired processing of human proIAPP exacerbates islet transplant failure, speculating that it may also contribute to diabetes. Together, these findings may implicate IAPP precursors as cytotoxic species in the beta cell and as potential biomarkers of beta cell dysfunction.
